CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Authors

Bernard Escudier

Published

March 3, 2017

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

European Urology

Topics

Pulmonary And Respiratory Medicine

DOI

10.1016/j.eururo.2017.02.010

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Authors

Bernard Escudier

Published

March 3, 2017

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

European Urology

Topics

Pulmonary And Respiratory Medicine

DOI

10.1016/j.eururo.2017.02.010

Paper

Paper

Paper

Paper

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Supporters

Journal

Topics

DOI

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Supporters

Journal

Topics

DOI